1. bookTom 60 (2022): Zeszyt 2 (June 2022)
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2501-062X
Pierwsze wydanie
30 Mar 2015
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
access type Otwarty dostęp

COVID-19: a trigger for severe thrombotic microangiopathy in a patient with complement gene variant

Data publikacji: 14 Jun 2022
Tom & Zeszyt: Tom 60 (2022) - Zeszyt 2 (June 2022)
Zakres stron: 138 - 142
Otrzymano: 24 Dec 2021
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2501-062X
Pierwsze wydanie
30 Mar 2015
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
Abstract

The evidence regarding thrombotic microangiopathy (TMA) related to Coronavirus Infectious Disease 2019 (COVID-19) in patients with complement gene mutations as a cause of acute kidney injury (AKI) are limited. We presented the case of a 23-year-old male patient admitted with an asymptomatic form of COVID-19, but with uncontrolled hypertension and AKI. Kidney biopsy showed severe lesions of TMA. In evolution patient had persistent microangiopathic hemolytic anemia, decreased level of haptoglobin and increased LDH level. Decreased complement C3 level and the presence of schistocytes were found for the first time after biopsy. Kidney function progressively decreased and the patient remained hemodialysis dependent. Complement work-up showed a heterozygous variant with unknown significance in complement factor I (CFI) c.-13G>A, affecting the 5’ UTR region of the gene. In addition, the patient was found to be heterozygous for the complement factor H (CFH) H3 haplotype (involving the rare alleles of c.-331C>T, Q672Q and E936D polymorphisms) reported as a risk factor of atypical hemolytic uremic syndrome. This case of AKI associated with severe TMA and secondary hemolytic uremic syndrome highlights the importance of genetic risk modifiers in the alternative pathway dysregulation of the complement in the setting of COVID-19, even in asymptomatic forms.

Keywords

1. NG J.H., BIJOL V., SPARKS M.A., SISE M.E., IZZEDINE H., JHAVERI K.D. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis. 2020; 27(5):365–76.10.1053/j.ackd.2020.09.003757472233308501Search in Google Scholar

2. VILLE S., LE BOT S., CHAPELET-DEBOUT A., BLANCHO G., FREMEAUX-BACCHI V., DELTOMBE C., et al. Atypical HUS relapse triggered by COVID-19. Kidney Int [Internet]. 2021; 99(1):267–8.10.1016/j.kint.2020.10.030765701733188793Search in Google Scholar

3. MAT O., GHISDAL L., MASSART A., AYDIN S., GOUBELLA A., BLANKOFF N., et al. Kidney Thrombotic Microangiopathy After COVID-19 Associated With C3 Gene Mutation. Kidney Int Reports. 2021;6(6):1732–7.10.1016/j.ekir.2021.03.897802869833851069Search in Google Scholar

4. KAUFELD J.K., REINHARDT M., SCHRÖDER C., BRÄSEN J.H., WIECH T., BRYLKA P., et al. Atypical HUS triggered by infection with SARS-CoV2. Kidney Int Reports. 2021; 6(10):2709-2712.10.1016/j.ekir.2021.07.004826521034258481Search in Google Scholar

5. ABDEL-WAHAB N., LOPEZ-OLIVO M.A., PINTO-PATARROYO G.P., SUAREZ-ALMAZOR M.E. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. 2016; 25(14):1520-1531.10.1177/0961203316640912750815927060064Search in Google Scholar

6. HARZALLAH I., DEBLIQUIS A., DRÉNOU B. Frequency of lupus anticoagulant in COVID-19 patients. Journal of Thrombosis and Haemostasis. 2020; 18(10):2778.10.1111/jth.14937728364032470207Search in Google Scholar

7. DEVREESE K.M.J., LINSKENS E.A., BENOIT D., PEPERSTRAETE H. Antiphospholipid antibodies in patients with COVID-19: A relevant observation?. J Thromb Haemost. 2020;18(9):2191–201.10.1111/jth.14994736125332619328Search in Google Scholar

8. PINETON DE CHAMBRUN M., FRERE C., MIYARA M., AMOURA Z., MARTIN-TOUTAIN I., MATHIAN A., et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?. Journal of Internal Medicine. 2021; 289(3):422-424.10.1111/joim.13126730703232529774Search in Google Scholar

9. TIWARI N.R., PHATAK S., SHARMA V.R., AGARWAL S.K. COVID-19 and thrombotic microangiopathies. Thromb Res. 2021; 202:191–198.10.1016/j.thromres.2021.04.012805592633894421Search in Google Scholar

10. YU J., YUAN X., CHEN H., CHATURVEDI S., BRAUNSTEIN E.M., BRODSKY R.A. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020; 136(18):2080–9.10.1182/blood.2020008248759684932877502Search in Google Scholar

11. NHLBI Exome Sequencing Project (ESP) Exome Variant Server [Internet]. Available from: http://evs.gs.washington.edu/EVS/Search in Google Scholar

12. CAPRIOLI J., CASTELLETTI F., BUCCHIONI S., BETTINAGLIO P., BRESIN E., PIANETTI G, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003; 12(24):3385–95.10.1093/hmg/ddg36314583443Search in Google Scholar

13. NEUMANN H.P.H., SALZMANN M., BOHNERT-IWAN B., MANNUELIAN T., SKERKA C, LENK D, et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet. 2003; 40(9):676–81.10.1136/jmg.40.9.676173558612960213Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo